Latest news with #Ezetimibe
Time of India
3 days ago
- Health
- Time of India
Is Trump hiding his health issues? Poll shows majority skeptical of US President's transparency
Live Events What White House said about Trump's health Biden's health (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel President Donald Trump is not being transparent about his health nearly half of Americans believe, according to a new poll. A recent YouGov/Economist poll conducted from May 23 to 26 among 1,660 adults revealed that 45% of respondents felt Donald Trump has been "not at all" or "not very" transparent about his health, while 42% believed he had been more forthcoming. The poll carries a margin of error of ±3.2 percentage points, reported results underscore a key challenge for Trump as he seeks to maintain public trust amid ongoing scrutiny of his 78 years and seven months, Trump was the oldest person ever inaugurated as US president. His election followed a campaign marked by concerns over the age and health of the candidates. Questions about Trump's physical and mental condition have persisted, particularly given a family history of dementia. Nonetheless, the White House physician stated in April that Trump is in "excellent cognitive and physical health."The poll also found mixed public perceptions of Trump's fitness for office: 31% said his age and health severely impair his ability to serve, 30% believed they had little impact, and 29% felt they had no impact at 62% of respondents said presidents should publicly release all medical information relevant to their ability to serve, while 28% argued that presidents should retain the same privacy rights as any other citizen regarding their health Trump is in "excellent cognitive and physical health", his White House physician said in April. In the first annual physical of his second presidential term at a Washington DC-area hospital, Trump was also found to have scarring "on the right ear from a gunshot wound", after an assassination attempt last July."President Trump remains in excellent health, exhibiting robust cardiac, pulmonary, neurological, and general physical function," his doctor, Captain Sean Barbabella, said in a memo. "President Trump exhibits excellent cognitive and physical health and is fully fit to execute the duties of the Commander-in-Chief and Head of State," Dr Barbabella wrote in the Barbabella reported that Trump has 'minor sun damage' and a few 'benign skin lesions.'According to the memo, the former president is taking several medications to manage his health: Rosuvastatin and Ezetimibe for cholesterol, Aspirin for heart disease prevention, and Mometasone cream for a skin cardiac evaluation revealed no abnormalities, Dr. Barbabella report also referenced a history of well-managed hypercholesterolemia, a condition that can elevate the risk of heart attack. Additional medical history included a previous COVID-19 infection, rosacea—a skin condition that often causes facial redness—and a benign colon Barbabella's records list Trump's weight at 224 pounds (101 kg) and his height at 6 feet 2.5 inches. This marks a weight loss since February 2019, when he weighed 243 President Joe Biden, 82, recently revealed he had been diagnosed with aggressive prostate cancer, reigniting concerns over transparency regarding his health.A survey found that 61 percent of respondents felt Biden had not been open about his medical condition, while only 31 percent believed he had been withdrew from the 2024 presidential race after a debate performance that intensified public concerns about his health and cognitive abilities. Just months earlier, in February 2024, his physician at Walter Reed National Military Medical Center had declared him "fit to serve" following a routine physical. Despite this, Biden and his campaign downplayed questions about his mental sharpness after the debate. The perception of a lack of transparency grew, with 57 percent of those surveyed believing that Democrats intentionally withheld information about his health while he was in an Oval Office press briefing last week, Trump criticized Biden's former medical team, suggesting they withheld critical health information from the public, and labeled the situation as "dangerous for our country.""I think somebody is going to have to speak to his doctor if it's the same, or even if it's two separate doctors," Trump said. "Why wasn't the cognitive ability, why wasn't that discussed? And I think the doctor said he's just fine. And it's turned out that's not so. It's very dangerous."
Malaysian Reserve
23-05-2025
- Health
- Malaysian Reserve
Sivem ezetimibe 10 mg tablets: One lot recalled as some bottles may contain perindopril 4 mg tablets
OTTAWA, ON, May 23, 2025 /CNW/ – Summary Product: Sivem ezetimibe 10 mg tablets Issue: Health products – Product safety What to do: If your bottle of ezetimibe 10 mg tablets contains any perindopril 4 mg tablets, or if you are unsure, return it to your pharmacy immediately. If you are unable to return your tablets to the pharmacy right away, talk to your pharmacist or doctor for further guidance. Seek immediate medical attention if you are experiencing serious side effects, including symptoms of a severe allergic reaction, such as difficulty breathing or swallowing or severe swelling of the lips, mouth or throat. Affected products Product DIN Lot number Expiry date Sivem ezetimibe 10 mg tablets 02429659 100063638 2026-07-31 Issue Sivem Pharmaceuticals ULC is recalling one lot of Sivem ezetimibe 10 mg tablets because some bottles may also contain perindopril 4 mg tablets. Taking perindopril when prescribed ezetimibe may pose serious health risks. Ezetimibe is a prescription drug used by adults and children 10 years of age and older to lower cholesterol and other fats in the blood. Perindopril is a prescription drug used in adults to treat high blood pressure. Patients not normally prescribed perindopril may experience side effects such as a drop in blood pressure, dizziness, light-headedness or fainting. Other possible effects could include headache, cough, or gastrointestinal discomfort (e.g., nausea, vomiting or diarrhea). The risk can be higher in people with low blood pressure, kidney problems, or those taking other medications that affect blood pressure. Patients unknowingly taking a medication could also have a severe allergic reaction to that medication. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to prevent this issue from reoccurring. The Department will inform the public if any new health risks are identified. What you should do Check your medication bottle to ensure it only contains Sivem ezetimibe 10 mg tablets. Sivem ezetimibe 10 mg is a white oblong tablet, with '93' stamped on one side and 'A11' on the other. Perindopril 4 mg is a spotted light green oblong tablet, with '4' stamped on one side and nothing stamped on the other. The tablet is scored (indented) on both middle edges. If the bottle contains any unusual tablets, or if you are unsure, return it to your pharmacy immediately. Your pharmacist will check the tablets and provide you with a replacement, if needed. If you are unable to return your tablets to the pharmacy right away, talk to your pharmacist or doctor for further guidance. Seek immediate medical attention if you are experiencing serious side effects (e.g., dizziness, light-headedness or fainting, or severe allergic reaction). If you have questions about this recall, contact Sivem Pharmaceuticals by calling 1-855-757-4836 or by emailing drugsafety@ Report any health product-related side effects or complaints to Health Canada. Sivem ezetimibe 10 mg is a white oblong tablet, with '93' stamped on one side and 'A11' on the other. Perindopril 4 mg is a spotted light green oblong tablet, with '4' stamped on one side and nothing stamped on the other. The tablet is scored (indented) on both middle edges. Additional information for health professionals: Health care professionals, such as pharmacists, should check bottles of Sivem ezetimibe 10 mg tablets before dispensing to ensure they do not contain perindopril 4 mg tablets. Report any unusual bottles or other issues to the company and to Health Canada. Également disponible en français
Cision Canada
23-05-2025
- Health
- Cision Canada
Public Advisory - Sivem ezetimibe 10 mg tablets: One lot recalled as some bottles may contain perindopril 4 mg tablets Français
Product: Sivem ezetimibe 10 mg tablets Issue: Health products – Product safety What to do: If your bottle of ezetimibe 10 mg tablets contains any perindopril 4 mg tablets, or if you are unsure, return it to your pharmacy immediately. If you are unable to return your tablets to the pharmacy right away, talk to your pharmacist or doctor for further guidance. Seek immediate medical attention if you are experiencing serious side effects, including symptoms of a severe allergic reaction, such as difficulty breathing or swallowing or severe swelling of the lips, mouth or throat. Affected products Issue Sivem Pharmaceuticals ULC is recalling one lot of Sivem ezetimibe 10 mg tablets because some bottles may also contain perindopril 4 mg tablets. Taking perindopril when prescribed ezetimibe may pose serious health risks. Ezetimibe is a prescription drug used by adults and children 10 years of age and older to lower cholesterol and other fats in the blood. Perindopril is a prescription drug used in adults to treat high blood pressure. Patients not normally prescribed perindopril may experience side effects such as a drop in blood pressure, dizziness, light-headedness or fainting. Other possible effects could include headache, cough, or gastrointestinal discomfort (e.g., nausea, vomiting or diarrhea). The risk can be higher in people with low blood pressure, kidney problems, or those taking other medications that affect blood pressure. Patients unknowingly taking a medication could also have a severe allergic reaction to that medication. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to prevent this issue from reoccurring. The Department will inform the public if any new health risks are identified. What you should do Check your medication bottle to ensure it only contains Sivem ezetimibe 10 mg tablets. Sivem ezetimibe 10 mg is a white oblong tablet, with "93" stamped on one side and "A11" on the other. Perindopril 4 mg is a spotted light green oblong tablet, with "4" stamped on one side and nothing stamped on the other. The tablet is scored (indented) on both middle edges. If the bottle contains any unusual tablets, or if you are unsure, return it to your pharmacy immediately. Your pharmacist will check the tablets and provide you with a replacement, if needed. If you are unable to return your tablets to the pharmacy right away, talk to your pharmacist or doctor for further guidance. Seek immediate medical attention if you are experiencing serious side effects (e.g., dizziness, light-headedness or fainting, or severe allergic reaction). If you have questions about this recall, contact Sivem Pharmaceuticals by calling 1-855-757-4836 or by emailing [email protected]. Report any health product-related side effects or complaints to Health Canada. Additional information for health professionals: Health care professionals, such as pharmacists, should check bottles of Sivem ezetimibe 10 mg tablets before dispensing to ensure they do not contain perindopril 4 mg tablets. Report any unusual bottles or other issues to the company and to Health Canada.
Yahoo
23-05-2025
- Health
- Yahoo
Public Advisory - Sivem ezetimibe 10 mg tablets: One lot recalled as some bottles may contain perindopril 4 mg tablets
OTTAWA, ON, May 23, 2025 /CNW/ - Summary Product: Sivem ezetimibe 10 mg tablets Issue: Health products – Product safety What to do: If your bottle of ezetimibe 10 mg tablets contains any perindopril 4 mg tablets, or if you are unsure, return it to your pharmacy immediately. If you are unable to return your tablets to the pharmacy right away, talk to your pharmacist or doctor for further guidance. Seek immediate medical attention if you are experiencing serious side effects, including symptoms of a severe allergic reaction, such as difficulty breathing or swallowing or severe swelling of the lips, mouth or throat. Affected products Product DIN Lot number Expiry date Sivem ezetimibe 10 mg tablets 02429659 100063638 2026-07-31 Issue Sivem Pharmaceuticals ULC is recalling one lot of Sivem ezetimibe 10 mg tablets because some bottles may also contain perindopril 4 mg tablets. Taking perindopril when prescribed ezetimibe may pose serious health risks. Ezetimibe is a prescription drug used by adults and children 10 years of age and older to lower cholesterol and other fats in the blood. Perindopril is a prescription drug used in adults to treat high blood pressure. Patients not normally prescribed perindopril may experience side effects such as a drop in blood pressure, dizziness, light-headedness or fainting. Other possible effects could include headache, cough, or gastrointestinal discomfort (e.g., nausea, vomiting or diarrhea). The risk can be higher in people with low blood pressure, kidney problems, or those taking other medications that affect blood pressure. Patients unknowingly taking a medication could also have a severe allergic reaction to that medication. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to prevent this issue from reoccurring. The Department will inform the public if any new health risks are identified. What you should do Check your medication bottle to ensure it only contains Sivem ezetimibe 10 mg tablets. Sivem ezetimibe 10 mg is a white oblong tablet, with "93" stamped on one side and "A11" on the other. Perindopril 4 mg is a spotted light green oblong tablet, with "4" stamped on one side and nothing stamped on the other. The tablet is scored (indented) on both middle edges. If the bottle contains any unusual tablets, or if you are unsure, return it to your pharmacy immediately. Your pharmacist will check the tablets and provide you with a replacement, if needed. If you are unable to return your tablets to the pharmacy right away, talk to your pharmacist or doctor for further guidance. Seek immediate medical attention if you are experiencing serious side effects (e.g., dizziness, light-headedness or fainting, or severe allergic reaction). If you have questions about this recall, contact Sivem Pharmaceuticals by calling 1-855-757-4836 or by emailing drugsafety@ Report any health product-related side effects or complaints to Health Canada. Additional information for health professionals: Health care professionals, such as pharmacists, should check bottles of Sivem ezetimibe 10 mg tablets before dispensing to ensure they do not contain perindopril 4 mg tablets. Report any unusual bottles or other issues to the company and to Health Canada. Également disponible en français SOURCE Health Canada (HC) View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-05-2025
- Health
- Yahoo
New cholesterol drug lowers LDL when statins aren't enough, study finds
A new medication that combines an already approved drug with a new unapproved one has been shown to cut the level of LDL, or 'bad' cholesterol, when statins aren't helping enough. In the Phase 3 trial, Cleveland Clinic researchers found that the combination of the new drug, obicetrapib, with an established medication, ezetimibe, reduced low-density lipoprotein (LDL) cholesterol levels by 48.6% after about three months' use — producing more effective results than either drug alone. Ezetimibe is a cholesterol-lowering drug that is often prescribed with statins to reduce LDL even more. The research was presented Wednesday during a late-breaking science session at the annual meeting of the European Atherosclerosis Society in Glasgow, Scotland, and simultaneously published in The Lancet. In the multicenter clinical trial, the lead researcher, Dr. Ashish Sarraju, a preventive cardiologist at the Cleveland Clinic, and his colleagues enrolled 407 patients with a median age of 68 with LDL cholesterol levels greater than 70 mg/dL even though they had taken medication to lower it. The participants were randomly assigned to four groups: a group for a pill that combined obicetrapib with ezetimibe, a group for each of the drugs separately and a placebo group. All participants continued on the medications they were taking before they started the trial, along with the medications being studied. The reason: Some people have to take a number of prescriptions to get LDL down to desired levels. 'We need to give patients and their doctors all the options we can to try to get LDL under control if they are at risk for, or already have, cardiovascular disease,' Sarraju said. 'In higher-risk patients, you want to get LDL down as quickly as possible and keep it there as long as possible.' High-risk patients either had had strokes or heart attacks or were likely to in the future. For that reason, the researchers enrolled patients in the trial who, despite already being on statins or even high-intensity statins, still had LDL levels that were too high. The hope is that lowering LDL levels will reduce the risk of adverse cardiovascular events such as strokes and heart attacks. According to the American Heart Association, the optimal total cholesterol level for an adult is about 150 mg/dL, with LDL levels at or below 100 mg/dL ('dL' is short for 'deciliter,' or a tenth of a liter). For high-risk patients, Sarraju recommends an LDL no higher than 70 mg/dL. The trial was funded by the maker of obcetrapib, Netherlands-based NewAmsterdam Pharma. It expects to have conversations with the Food and Drug Administration about approval for the new combo drug 'over the course of the year,' a spokesperson said. A multitude of modifiable factors can result in high LDL, such as a diet high in saturated fats, processed foods and fried foods; being overweight; smoking; and older age. Dr. Robert Rosenson, director of lipids and metabolism for the Mount Sinai Health System in New York City, said other drugs in the same class have failed to reduce heart attacks or stroke, 'but I am cautiously hopeful.' The drugmaker is currently running an additional trial to determine if the combo drug not only lowers cholesterol but also protects against adverse heart events. While lifestyle changes can help bring down LDL, levels remain stubbornly high for some people. Only 20% of patients at high risk of heart disease are able to manage their LDL, said Dr. Corey Bradley, a cardiologist at the Columbia University Vagelos College of Physicians and Surgeons. Heart disease is the leading cause of death for adults in the United States. 'High LDL is one of the leading risk factors for heart disease, and we have such a poor handle on controlling that risk,' Bradley said. 'Many people have such a high LDL they will require multiple agents to control it.' 'I am very excited about drugs like obicetrapib,' she said. This article was originally published on
